Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Newly Admitted Psychiatric Patient Prescriptions and Pharmaceutical Sales Visits

Newly Admitted Psychiatric Patient Prescriptions and Pharmaceutical Sales Visits There is much literature regarding the interaction of pharmaceutical sales representatives and physicians. However, there is little information available regarding their interactions with psychiatric residents. This paper attempts to quantify the impact of pharmaceutical sales visits upon prescriptions written for newly admitted patients in a psychiatric residency training clinic. A retrospective chart review of 47 consecutive patients was conducted. At the time of review all included patients had been admitted to the clinic for less than 3 months. Their psychiatric medication regimens were followed for 3 months. Initiation of new psychotropics was recorded. Data was also collected regarding the number of sales visits which typically occur at resident luncheons. Statistical analysis compared the number of new medication starts to the number of sales visits. Twelve pharmaceutical companies made sales visits. Eleven out of 12 companies' visits were statistically associated with an increase in new medication starts (p < 0.05). As the number of sales visits increased, a greater statistical significance was noted. This study is one of the first to quantify pharmaceutical industry's impact on psychiatric residents' prescribing practices. It appears that psychiatric residents preferentially start companies' medications shortly after sales visits. Furthermore, as sales visits increase in frequency, more of their medications may be started in newly admitted psychiatric outpatients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Newly Admitted Psychiatric Patient Prescriptions and Pharmaceutical Sales Visits

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/newly-admitted-psychiatric-patient-prescriptions-and-pharmaceutical-01s6J1KJaF
Publisher
Springer Journals
Copyright
Copyright © 2001 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1012237709036
Publisher site
See Article on Publisher Site

Abstract

There is much literature regarding the interaction of pharmaceutical sales representatives and physicians. However, there is little information available regarding their interactions with psychiatric residents. This paper attempts to quantify the impact of pharmaceutical sales visits upon prescriptions written for newly admitted patients in a psychiatric residency training clinic. A retrospective chart review of 47 consecutive patients was conducted. At the time of review all included patients had been admitted to the clinic for less than 3 months. Their psychiatric medication regimens were followed for 3 months. Initiation of new psychotropics was recorded. Data was also collected regarding the number of sales visits which typically occur at resident luncheons. Statistical analysis compared the number of new medication starts to the number of sales visits. Twelve pharmaceutical companies made sales visits. Eleven out of 12 companies' visits were statistically associated with an increase in new medication starts (p < 0.05). As the number of sales visits increased, a greater statistical significance was noted. This study is one of the first to quantify pharmaceutical industry's impact on psychiatric residents' prescribing practices. It appears that psychiatric residents preferentially start companies' medications shortly after sales visits. Furthermore, as sales visits increase in frequency, more of their medications may be started in newly admitted psychiatric outpatients.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 19, 2004

References

  • Doctors, drug companies, and gifts
    Chren, M; Landefeld, CS; Murray, TH
  • Separating the wheat from the chaff: Identifying fallacies in pharmaceutical promotion
    Shaughnessy, AF; Slawson, DC; Bennett, JH
  • Interactions between physicians and the pharmaceutical industry: What does the literature say?
    Lexchin, J
  • When pharmaceutical manufacturers' employees present grand rounds, what do residents' remember?
    Springarn, RW; Berlin, JA; Strom, BL
  • Pharmaceutical representatives in academic medical centers: Interaction with faculty and housestaff
    Lurie, N; Rich, EC; Simpson, DE; Meyer, J; Schiedenmayer, DL; Goodman, JL; McKinney, WP
  • Of principles and pens: Attitudes and practices of medicine housestaff towards pharmaceutical industry promotions
    Steinman, MA; Shlipak, MG; McPhee, SJ
  • Gifts to physicians in the consumer marketing era
    Steinman, MA
  • Interactions with the pharmaceutical industry: A survey of family medicine residents in Ontario
    Sergeant, MD; Hodgetts, PG; Godwin, M; Walker, DM; McHenry, P
  • Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry
    Keim, SM; Sanders, AB; Witzke, DB; Dyne, P; Fulginiti, JW
  • Pharmaceutical representatives and emergency residents: A national survey
    Reeder, M; Dougherty, J; White, LJ
  • Interactions with the pharmaceutical industry: Experiences and attitudes of psychiatry residents, interns and clerks
    Hodges, B
  • Pharmaceutical industry impact on psychiatry residents' prescribing practices
    Schwartz, TL; Kuhles, DJ; Beeber, AR; Gregory, RJ; Masand, PS